Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 139 of the 139 references it cites were found in a registry or an index.

Targeting RAS–ERK signalling in cancer: promises and challenges

Samatar, Ahmed A., Poulikakos, Poulikos I. · 2014 · Nature Reviews Drug Discovery

Abstract

The RAS-RAF-MEK-ERK signalling pathway is hyperactivated in a high percentage of tumours, most frequently owing to activating mutations of the KRAS, NRAS and BRAF genes. Recently, the use of compounds targeting components of ERK signalling, such as RAF or MEK inhibitors, has led to substantial improvement in clinical outcome in metastatic melanoma and has shown promising clinical activity in additional tumour types. However, response rates are highly variable and the efficacy of these drugs is primarily limited by the development of resistance. Both intrinsic and acquired resistance to RAF and MEK inhibitors are frequently associated with the persistence of ERK signalling in the presence of the drug, implying the need for more innovative approaches to target the pathway.

Overview

Integrity signals

Registry

Crossref · 10.1038/nrd4281

Cites

139 of 139 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 139 references

Cited by

See all 1,163

Metadata

Authors
Samatar, A. A., & Poulikakos, P. I.
Affiliations
Tisch Cancer Institute (US)
Corresponding author
Poulikakos, Poulikos I.
Venue
Nature Reviews Drug Discovery
Published
2014-12
Volume
13
Issue
12
Pages
928-942
ISSN
  • 1474-1776 (ISSN-L)
  • 1474-1784
OpenAlex
W2050573392
Cited by
1,163
References
139
Citations by year
2026: 47 · 2025: 77 · 2024: 106 · 2023: 100 · 2022: 102 · 2021: 134 · 2020: 119 · 2019: 105 · 2018: 117 · 2017: 101 · 2016: 108 · 2015: 45 · 2014: 2
FWCI
8.07
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Nature Reviews Drug Discovery (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
Keywords
RAF inhibitors, MEK inhibitors, ERK inhibitor, KRAS mutation, NRAS mutation, BRAF mutation, acquired drug resistance, intrinsic drug resistance, metastatic melanoma, targeted cancer therapy, drug development
MeSH terms
Animals, Antineoplastic Agents, Humans, Neoplasms, Drug Delivery Systems, ras Proteins, MAP Kinase Signaling System, Protein Kinase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting RAS–ERK signalling in cancer: promises and challenges. https://app.cochat.ai/papers/10.1038/nrd4281
The paper
Samatar, A. A., & Poulikakos, P. I. (2014). Targeting RAS–ERK signalling in cancer: promises and challenges. Nature Reviews Drug Discovery. https://doi.org/10.1038/nrd4281

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.